Here's why Biogen's promising Alzheimer's drug data is also good news for Eli Lilly

We don't own Eli Lilly exclusively for its potential Alzheimer's treatment. However, we still find Biogen's topline data to be very encouraging for Lilly.

from Health and Science https://ift.tt/bWGEmBa
https://ift.tt/WUK6v9I
https://ift.tt/dlNEU8e